Description

Methotrexate Hydrate is a potent folate antagonist and antimetabolite widely recognized for its critical role in chemotherapy and immunosuppressive therapy. Its primary value lies in its ability to inhibit dihydrofolate reductase, effectively disrupting DNA synthesis and cellular replication. This makes it an essential active pharmaceutical ingredient (API) for pharmaceutical manufacturers and research institutions developing treatments for oncology, autoimmune diseases, and severe psoriasis. The compound is supplied with rigorous quality control to ensure consistency and efficacy for demanding therapeutic applications.

Application

• Oncological Therapeutics: A cornerstone chemotherapeutic agent for treating various cancers, including acute lymphoblastic leukemia, non-Hodgkin lymphoma, osteosarcoma, and breast cancer.
• Autoimmune Disease Management: Key immunosuppressant used in the treatment of rheumatoid arthritis, psoriasis, and Crohn's disease to modulate the immune response.
• Pharmaceutical Formulation: Serves as the core Active Pharmaceutical Ingredient (API) in the production of injectable solutions, tablets, and other dosage forms.
• Medical Research & Development: Utilized in biochemical and pharmacological studies to investigate mechanisms of folate metabolism, cell proliferation, and new therapeutic combinations.
• Dermatology Treatments: Employed in systemic therapy for severe, disabling psoriasis that is unresponsive to other forms of treatment.
• Ectopic Pregnancy Treatment: Used as a non-surgical medical treatment option for certain cases of ectopic pregnancy.

Basic Information

Product Name	Methotrexate Hydrate
CAS No.	133073-73-1
Molecular Formula	C₂₀H₂₂N₈O₅ • xH₂O
Molecular Weight	454.44 g/mol (Anhydrous basis)
Synonyms	Methotrexate Monohydrate; Amethopterin; MTX; (2S)-2-[(4-{[(2,4-Diaminopteridin-6-yl)methyl](methyl)amino}benzoyl)amino]pentanedioic acid; Rheumatrex; Trexall; 4-Amino-10-methylfolic acid; NSC-740
EINECS	Contact for details

Quality Control

Our Methotrexate Hydrate is manufactured and tested to meet high-purity standards suitable for pharmaceutical applications. Quality assurance protocols are aligned with current industry practices, and production can be tailored to comply with relevant pharmacopoeial monographs (e.g., USP, EP, BP). A comprehensive Certificate of Analysis (COA) is provided with each batch, detailing purity, identity, and impurity profiles to ensure traceability and compliance.

Storage

Preserve in a tightly closed container, protected from light. Store in a cool, dry place at a controlled room temperature (15-25°C). This product is hygroscopic (moisture-sensitive) and must be kept in a dry environment to prevent degradation. For long-term stability, consider storage under inert atmosphere.

Specification

Item	Specification
Appearance	Yellow to orange crystalline powder
Identification (IR)	Conforms to standard
Identification (HPLC)	Retention time matches reference standard
Assay (HPLC)	≥98.0% (on anhydrous basis)
Water Content (KF)	≤8.5%
Related Substances (HPLC)	Total impurities ≤2.0% Any single impurity ≤0.5%
Residue on Ignition	≤0.1%
Heavy Metals	≤20 ppm

Note: Specifications can be tailored. Please contact us for the detailed technical data sheet of a specific grade.